ArticleMolecular cancer research : MCR2018
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
Article in Molecular cancer research : MCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.World journal of urology · 2020Pooled it
- Circulating tumour cells as a window into lethality in prostate cancer.Nature reviews. Urology · 2026Review
- Circulating tumor cell-based PSMA and PSA expression as a predictive and prognostic tool in prostate cancer.Translational cancer research · 2025Article
- Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients.Breast cancer research and treatment · 2022Article
- Fatty Acid Signaling Impacts Prostate Cancer Lineage Plasticity in an Autocrine and Paracrine Manner.Cancers · 2022Article
- Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.The Prostate · 2022Review
- Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).International journal of molecular sciences · 2021Article
- Noncoding RNAs in tumor metastasis: molecular and clinical perspectives.Cellular and molecular life sciences : CMLS · 2021Review
- Wnt and β-Catenin Signaling in the Bone Metastasis of Prostate Cancer.Life (Basel, Switzerland) · 2021Review
- Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer.Cell death & disease · 2021Article
- Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.Journal of personalized medicine · 2021Review
- Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.Clinical & experimental metastasis · 2021Article
- Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication.Molecular cancer · 2021Review
- Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.Cancer science · 2021Article
- Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion.Translational oncology · 2020Article
- Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.The Prostate · 2019Article
- Detection of Androgen Receptor Variant 7 (Cells · 2019Article
- Article
- Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.Neoplasia (New York, N.Y.) · 2019Article
- The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
Abstract
The trend toward precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration-resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer-related genes. CTCs were isolated from the whole blood of mCRPC patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.